Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by DrHolidayon Jun 28, 2018 5:05pm
145 Views
Post# 28247664

RE:since june 18 163,104,589 million shares flipped

RE:since june 18 163,104,589 million shares flippedBased on the recent news, I think at least 60% of the volume was purchased by new shareholders and sold to by profit takers, and now concentrated into stronger hands, however 40% of this total volume is probably pennyflippers (daytraders) generating back and forth volume and playing the spread up and down.
The good news is that since this type of trading does generate high volume, it presents real investors with an opportunity to accumulate by buying the dips caused by this volatility.
We can only guess how much volume was short covering.

A big chunk of the cheap paper below the 7 cent level has been turned over like a steak being cooked on a barbecue grill.
Well done with garlic salt and pepper.


<< Previous
Bullboard Posts
Next >>